Five-membered heterocycles represent approximately half of the top 20 most common aromatic ring systems present in biologically active compounds.^[@ref1]^ They also frequently occur in natural products.^[@ref2]^ Their relative ease of synthesis from readily available precursors and their steric and electronic plasticity contribute to this popularity. As an extension of our synthetic studies on anticancer furans,^[@ref3]^ thiophenes,^[@ref4]^ oxazoles,^[@ref5]^ and thiazoles,^[@ref6]^ we became interested in the attractive cell-specific toxicity profile (i.e., the hyperselective growth inhibition) of terfuran **1**, in comparison to the broad-based toxicity of the thiophene-furan heterocyclic triad RITA (**2**, Figure [1](#fig1){ref-type="fig"}).^[@ref7]^ The latter compound, also known as NSC 652287, has been shown to exhibit potent antiproliferative activity in various cancer cell lines, in particular in the renal cell line A498.^[@ref8]^ The mechanism of action of **2** has been the topic of much speculation. An interaction between **2** and the *N*-terminal domain of p53 was suggested to interfere with HDM2 binding and degradation of p53.^[@ref9]^ Other p53-mediated functions such as the regulation of pro- and antiapoptotic genes are also influenced by **2**, in addition to induction of autophagy, downregulation of c-Myc, cyclin E and β-catenin oncogene expression, and inhibition of the PI3K/Akt signaling pathway.^[@ref10]^ Among a series of analogues of **2**, terthiophene **3** was recently found to exhibit only weak activity against a p53 knockout cancer cell line but activated p53 and triggered apoptosis in wild-type HCT116 at low nanomolar concentrations.^[@ref11]^ The primary alcohol group in these compounds proved to be essential for bioactivity and possibly acts as a prodrug that is metabolized to the active agent within the cell.^[@ref12]^ Interestingly, the corresponding esters and aldehydes were significantly less active in the National Cancer Institute NCI-60 screen.^[@ref13]^

![Structures of selective antiproliferative furan and thiophene triads **1**, RITA (*r*eactivation of p53 and *i*nduction of *t*umor cell *a*poptosis, **2**), and **3**.](ol-2014-00620m_0002){#fig1}

With the goal of improving synthetic accessibility and enabling further SAR studies of heterocyclic triads such as terfuran **1**,^[@ref7],[@ref11],[@ref14]^ which provides hyperselective inhibition of exceptionally responding cells, we developed two alternative strategies to attach substituted heterocycles to a dihalogenated core. First, we utilized the Suzuki--Miyaura cross-coupling of commercially available furan boronic acid **5a** and readily accessible dibrominated heterocycles **4a**--**c** to prepare dialdehydes **6a**--**c** (Scheme [1](#sch1){ref-type="scheme"}). After screening several Pd(0)/ligand combinations, we found that Pd~2~(dba)~3~ and tri-*tert*-butylphosphine under microwave conditions provided the best yield of 51% for **6a**.^[@ref15]^ Other ligands such as JohnPhos, triisopropylphosphine, and tricyclohexylphosphine gave yields \<25% of **6a**. We also attempted to achieve a monocoupling of **5a** in the presence of an excess of dibromide **4a** and ligand XPhos;^[@ref16]^ however, bis-coupling product **6a** remained the major product. In comparison, Pd(PPh~3~)~4~ with tetra-*N*-butylammonium bromide as an additive mainly gave the monocoupled product.^[@ref17]^

![Tandem Suzuki--Miyaura Cross-Coupling of 2,5-Dibrominated Furan, Thiophene, and Selenophene and Reduction to Diols](ol-2014-00620m_0003){#sch1}

Bis-couplings at the 2,5-positions of dibrominated thiophene **4b** and selenophene **4c** were achieved in excellent yields under the conditions optimized for furan **4a** (Scheme [1](#sch1){ref-type="scheme"}). Interestingly, yellow precipitates of triads **6b** and **6c** formed at room temperature immediately after addition of the reaction components, and aldehyde **6b** was obtained in \>70% yield after stirring overnight. These mild conditions can improve the scalability of the cross-coupling process. While the coupling proceeds well even at room temperature, microwave heating, greatly expedited the completion of the reaction without causing decomposition. Finally, reduction with NaBH~4~ furnished the alcohols **1** and **7b**,**c** in excellent yields.

Regioisomeric thiophene analogues were obtained by bis-coupling of **5a** to 3,4-dibromothiophene (**4d**), 2,5-dimethyl-3,4-dibromothiophene (**4e**), and 2,4-dibromothiophene (**4f**) (Scheme [2](#sch2){ref-type="scheme"}). Due to the lower reactivity at C(3) of thiophene,^[@ref18]^ we increased catalyst loadings and equivalents of boronic acid **5a** in order to facilitate the formation of bis-coupled products. Finally, NaBH~4~ reduction furnished the diols **7d**--**f**. NMR analysis of the reaction mixture of analogue **7d** showed signs of decomposition after mild heating at ca. 50 °C, presumably due to side reactions as a consequence of the high reactivity of the unsubstituted thiophene C(2) and C(5) positions.

![Tandem Suzuki--Miyaura Cross-Coupling of 3,4-and 2,4-Dibrominated Thiophene and Reduction to Diols](ol-2014-00620m_0004){#sch2}

Lead structure **1** and analogues **7b**--**f** could be rapidly assembled using these optimized Suzuki--Miyaura conditions, adding two identical heterocyclic end groups to the core structure in one cross-coupling step. Moreover, a related stepwise approach was readily identified that allowed a variation of the terminal heterocycles and access to desymmetrized products. Commercially available bromothiophene **4g** and furan boronic acid **5b** were combined at C(5) and C(2), respectively, and the furan C(5) position was subsequently brominated with *N*-bromosuccinimide and benzoyl peroxide^[@ref19]^ to yield aldehyde **8** in 61% yield over the two steps (Scheme [3](#sch3){ref-type="scheme"}). Cross-coupling of **8** with furan boronic acid **5a** led to the bisfuranylthiophene triad **6g** in 78% yield, and reduction of the two aldehyde functional groups with NaBH~4~ provided diol **7g** in 90% yield.

![Sequential Suzuki--Miyaura Cross-Coupling of 5-Bromothiophene and Reduction to Diol](ol-2014-00620m_0005){#sch3}

A significant further diversification of the scaffold of the heterocyclic triads **1** and **7b**--**g** was envisioned by an isosteric replacement of the terminal furan and thiophene rings with oxazole moieties. However, while the requisite ethyl 2-iodo-4-oxazole carboxylate building block was readily prepared,^[@ref20]^ neither Suzuki--Miyaura nor Negishi cross-couplings provided more than trace amounts of the desired products.^[@ref21]^

The challenge of functionalizing and coupling oxazoles^[@ref22]^ can be addressed more directly with a regioselective arylation of a C(2)-unsubstituted oxazole. Hoarau's group, for example, reported a successful arylation of both the C(2)- and C(5)-positions of commercially available **9** using palladium catalysis.^[@ref23]^ The electron-withdrawing nature of the ester group in **9** was found to be important for the reactivity of the oxazole, particularly for the activation of the C(2) carbon--hydrogen bond. While our attempts to couple the alcohol and aldehyde derivatives of **9** under these conditions were unsuccessful, we found that reactivity is also influenced by the position of the ester substituent on the oxazole ring. When we attempted a coupling with ethyl 5-oxazole carboxylate, only 5% of the bis-coupled product was isolated, reinforcing the apparent need for an electron-withdrawing group at C(4). We were pleased to find that **9** underwent a C(2)-selective tandem C--H bond activation/cross-coupling with both **4b** and **4c** under Hoarau's conditions to furnish esters **10b** and **10c** in satisfactory yields (Scheme [4](#sch4){ref-type="scheme"}). Finally, LiAlH~4~ reduction provided access to the desired alcohols **11b** and **11c** in good yields.

![Sequential Pd-Catalyzed C--H Bond Activation/Cross Coupling of Oxazoles with Dibromothiophene and Dibromoselenophene and Reduction to Diol](ol-2014-00620m_0006){#sch4}

Diols **1**, **2**, **7b**--**e**,**g**, and **11b**,**c** as well as aldehyde **6c** were evaluated in the NCI 60-cell line panel^[@ref24]^ for selective anticancer activity.^[@ref25]^ Table [1](#tbl1){ref-type="other"} shows the concentrations required to achieve 50% growth inhibition (GI~50~) in the two most sensitive cancer cell lines.

With the exception of oxazole-containing analogues **11b** and **11c**, which provided no significant cell growth inhibition at 10 μM concentration, the heterocyclic triads were, in general, more toxic to the renal cell line A498 than other cell lines (Table [1](#tbl1){ref-type="other"}). Of the tested compounds, those with the 3,4-substitution pattern on a central thiophene, i.e., **7d** and **7e**, were the most potent, in addition to the desymmetrized triad **7g**, which combined two 2,5-substituted furans with a 2,5-substituted thiophene terminus. The latter compound is remarkably more potent (10×) than its sequence isomer **7b**. Overall, the cellular toxicity profiles of **7d**, **7e**, and **7g** were similar to compound **2**. On the other hand, compounds **7b** and **7c**, similar to **1**, were less potent but more hyperselective in the NCI 60-cell line panel (data not shown). Aldehyde **6c** also showed a significant 20-fold drop off in activity from the most sensitive cell line (A498) to the next most sensitive one (MCF7).

###### Growth Inhibition in Renal (A498), Lung (NCI-H226), Kidney (CAKI-1), and Breast (MDA-MB-468, MCF7) Cancer Cell Lines

  compd    NSC no.   GI~50~[a](#t1fn1){ref-type="table-fn"} (μM)   GI~50~[b](#t1fn2){ref-type="table-fn"} (μM)
  -------- --------- --------------------------------------------- ---------------------------------------------
  **1**    672348    0.18 (A498)                                   0.58 (NCI-H226)
  **2**    652287    0.012 (CAKI-1)                                0.015 (A498)
  **7b**   773097    0.13 (A498)                                   0.17 (MDA-MB-468)
  **6c**   773393    0.30 (A498)                                   6.3 (MCF7)
  **7c**   773392    0.17 (A498)                                   0.22 (MDA-MB-468)
  **7d**   777422    0.015 (A498)                                  0.074 (MDA-MB-468)
  **7e**   778301    0.016 (MDA-MB-468)                            0.018 (A498)
  **7g**   777196    0.016 (A498)                                  0.018 (MDA-MB-468)

Most sensitive cell line.

Next most sensitive cell line.

In conclusion, we have developed and optimized two complementary synthetic protocols for the preparation of the nine heterocyclic triads **1**, **7b**--**g**, and **11b**,**c**. First, we identified a catalytic Pd system for the direct Suzuki--Miyaura tandem cross-coupling of commercially available furan boronic acids with dibromofuran, -thiophene, and -selenophene. In a variation of this protocol, the sequential cross-coupling of a bromothiophene provided the desymmetrized triad **7g**. Second, we utilized a Pd-catalyzed C,H-bond activation at C(2) of oxazole ester **9** to assemble the bis-oxazole triads **11b** and **11c** from dibromothiophene **4b** and dibromoselenophene **4c** in good yields and high synthetic efficiency. Biological evaluation provided a significant extension of the SAR information available for the parent terfuran **1** and allows for an examination of the effects of heterocyclic sequence and connectivity patterns on cancer cell toxicity. Ongoing studies, including in vivo xenograft models, aim to determine if a broad spectrum pattern of high cellular activity (as demonstrated by **2**, **7d**, **7e**, and **7g**) or lower cellular activity paired with hyperselectivity (as demonstrated by **1**, **6c**, **7b**, and **7c**) are predictive of a greater therapeutic index in this series.

Experimental procedures and spectral data for all new or previously incompletely characterized compounds, including copies of ^1^H and ^13^C NMR spectra. This material is available free of charge via the Internet at <http://pubs.acs.org>.
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